Cargando…
Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma
Human intrahepatic cholangiocarcinomas are one of the most difficult cancers to treat. In our study, Lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme-CoA (HMG-CoA) reductase inhibitor, demonstrated anticancer properties by inhibiting cancer cell proliferation, cell migration and cell adhesion. Lova...
Autores principales: | Yang, Sheng-Huei, Lin, Hung-Yun, Changou, Chun A, Chen, Chun-Han, Liu, Yun-Ru, Wang, Jinghan, Jiang, Xiaoqing, Luh, Frank, Yen, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808004/ https://www.ncbi.nlm.nih.gov/pubmed/26517522 |
Ejemplares similares
-
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo
por: Yang, Sheng-Huei, et al.
Publicado: (2015) -
Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma
por: Wang, Jinghan, et al.
Publicado: (2015) -
Systemic and Adjuvant Therapies for Intrahepatic
Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017) -
Integrin β5 is an independent prognostic marker for intrahepatic cholangiocarcinoma in a Chinese population
por: Ma, Lixing, et al.
Publicado: (2023) -
Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma
por: Hung, Tsai‐Hsien, et al.
Publicado: (2021)